RA0497

antibody from Oursmab
Targeting: MS4A1 B1, Bp35, CD20, MS4A2
Provider product page for RA0497
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0497 - Provider product page
Provider
Oursmab
Product name
Obinutuzumab (Biosimilar Reference Antibody) (MS4A1)
Antibody type
Monoclonal
Description
Obinutuzumab (brand name Gazyva?/Gazyvaro?) is a humanized, glycoengineered type II anti-CD20 monoclonal antibody of the IgG1 isotype. Its Fc region is engineered to reduce fucose content, which enhances binding to Fc¦ÃRIIIa on immune effector cells (e.g., natural killer cells, macrophages), resulting in stronger antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) compared to earlier anti-CD20 antibodies like rituximab. As a type II antibody, it also induces direct, non-apoptotic cell death with weaker complement-dependent cytotoxicity (CDC). It is approved in combination with chemotherapy for the treatment of follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), and for previously untreated advanced FL in combination with bendamustine followed by obinutuzumab maintenance.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
MS4A1 protein structure - RA0497 shown in red.